Author: healthylife7

“Obtaining regulatory approval is one part of the challenge for rare disease therapies. Following approval, HTA agencies and payers evaluate the clinical, economic, and patient-centered value of a therapy to inform pricing, reimbursement, and patient access decisions. Historically, rare disease trials have often relied on small patient populations, single-arm or open-label designs, surrogate endpoints, and…

Read More